Reuters: Health
British drugmaker AstraZeneca on Tuesday said it expects to move two COVID-19 antibody based therapies it has licensed from U.S. researchers into clinical studies in the next two months as it ramps up efforts to help combat the pandemic.
No comments:
Post a Comment